BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Novo Nordisk (NYSE:NVO) but lowers the price target from $170 to $160.
August 08, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BMO Capital maintains an Outperform rating on Novo Nordisk but lowers the price target from $170 to $160.
The Outperform rating suggests continued confidence in Novo Nordisk's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100